14-day Premium Trial Subscription Sign Up For FreeGet Free

Stock Market Week 20 - The Game Is On! Click to watch.

Atara Biotherapeutics Stock Forecast

NASDAQ:ATRA BUY SELL

$5.30 (-3.28%)

Volume: 883.995k

Closed: May 16, 2022

Hollow Logo Score: -3.181

Atara Biotherapeutics Stock Forecast

BUY SELL NASDAQ:ATRA
$5.30 (-3.28%)

Volume: 883.995k

Closed: May 16, 2022

Score Hollow Logo -3.181

Atara Biotherapeutics Stock Forecast NASDAQ:ATRA

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-05-10 50.94% Citigroup $23.00 $8.00 Downgrades Buy Neutral
2022-03-28 315.09% JP Morgan $27.00 $22.00 Maintains Overweight
2022-01-03 409.43% JP Morgan $26.00 $27.00 Maintains Overweight
2021-05-13 447.17% JP Morgan $23.00 $29.00 Upgrades Neutral Overweight
2021-05-05 484.91% HC Wainwright & Co. $32.00 $31.00 Maintains Buy
2020-12-08 484.91% HC Wainwright & Co. $28.00 $31.00 Maintains Buy
2020-11-10 428.3% HC Wainwright & Co. $26.00 $28.00 Maintains Buy
2020-09-15 1371.7% Canaccord Genuity $70.00 $78.00 Maintains Buy
2020-08-06 428.3% Stifel $30.00 $28.00 Maintains Buy
2020-08-06 390.57% HC Wainwright & Co. $25.00 $26.00 Maintains Buy
2020-06-30 - Evercore ISI Group - Initiates Coverage On Outperform
2020-06-15 371.7% HC Wainwright & Co. $25.00 Initiates Coverage On Buy
2020-05-12 333.96% JP Morgan $22.00 $23.00 Maintains Neutral
2020-04-23 - Citigroup - Upgrades Neutral Buy
2019-11-08 315.09% JP Morgan $43.00 $22.00 Downgrades Overweight Neutral
2019-09-27 69.81% Goldman Sachs $14.00 $9.00 Downgrades Neutral Sell
2019-09-16 183.02% Jefferies $32.00 $15.00 Downgrades Buy Hold
2019-06-04 - Citigroup - Upgrades Sell Neutral
2019-05-30 466.04% Roth Capital $30.00 Initiates Coverage On Buy
2019-05-23 673.58% Stifel $41.00 Initiates Coverage On Buy

ATRA Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -45.80% during the next 3 months and, with a 90% probability hold a price between $2.54 and $4.03 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2022-05-18 $4.58 $5.95 $7.33
2022-05-19 $4.48 $5.85 $7.22
2022-05-20 $4.37 $5.75 $7.12
2022-05-23 $4.27 $5.64 $7.01
2022-05-24 $4.16 $5.54 $6.91
2022-05-25 $4.06 $5.43 $6.80
2022-05-26 $3.95 $5.33 $6.70
2022-05-27 $3.85 $5.22 $6.60
2022-05-31 $3.74 $5.12 $6.49
2022-06-01 $3.64 $5.01 $6.39
2022-06-02 $3.53 $4.91 $6.28
2022-06-03 $3.43 $4.80 $6.18
2022-06-06 $3.33 $4.70 $6.07
2022-06-07 $3.22 $4.59 $5.97
2022-06-08 $3.12 $4.49 $5.86
2022-06-09 $3.01 $4.38 $5.76
2022-06-10 $2.91 $4.28 $5.65
2022-06-13 $2.80 $4.18 $5.55
2022-06-14 $2.70 $4.07 $5.44
2022-06-15 $2.59 $3.97 $5.34
2022-06-16 $2.49 $3.86 $5.23
2022-06-17 $2.38 $3.76 $5.13
2022-06-21 $2.28 $3.65 $5.03
2022-06-22 $2.17 $3.55 $4.92
2022-06-23 $2.07 $3.44 $4.82
2022-06-24 $1.96 $3.34 $4.71
2022-06-27 $1.86 $3.23 $4.61
2022-06-28 $1.76 $3.13 $4.50
2022-06-29 $1.65 $3.02 $4.40
2022-06-30 $1.55 $2.92 $4.29

About Atara Biotherapeutics

Atara Biotherapeutics Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases. Its products under development include EBV-CTL, which is Phase II clinical trials for the treatment of malignancies associated with Epstein Barr Virus (EBV), including EBV-associated post-transplant lymphoproliferative disorders; CMV-CTL that is in Phase II clinical trials for the treatme... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 108 000+ Happy Subscribers

Don't miss out on the runners!

Sign for StockInvest.us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT